Digestive Diseases and Sciences

, Volume 47, Issue 2, pp 317–321 | Cite as

Colorectal Cancer Risk: The Impact of Evidence of a Field Effect of Carcinogenesis on Blinded Diagnosis Using an Anti-Adenoma Antibody Test Performed on Colonoscopic Effluent

  • Martin Tobi
  • Shivkumar Prabhu
  • Rhonda E. Gage
  • Tashia Orr
  • Michael J. Lawson


To better define high-risk populations for colorectal cancer screening, we used anti-adenoma antibody Adnab-9, comparing colonic effluent and tissue field effects from 45 high-risk and 11 control patients. We included Adnab-9 binding at the tissue level to elucidate the impact of a field effect of carcinogenesis contributing to the outcome of the effluent binding test. In high-risk patients, 64% of the left-sided effluent samples were positive (P < 0.002); 67% showed a field effect (P < 0.006); 82% of combined tests were positive (P < 0.001), as compared to 9%, 18%, and 27% respectively, of controls. Adnab-9 binding correlates with increased colorectal cancer risk associated with a field effect of carcinogenesis.

monoclonal antibodies colorectal neoplasia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Darmon E, Tobi M, Rozen P: Newer tests, on the colonic effluent, for identifying persons with colorectal neoplasia. In Frontiers of Gastrointestinal Research, Advances in Large Bowel Cancer: Policy, Prevention, Research and Treatment. P Rozen, CB Reich, SJ Winawer (eds). Basel Karger, 1991, pp 236–247Google Scholar
  2. 2.
    Rozen P, Tobi M, Darmon E, Kaufman L: Colonic cytology: A simplified method of collection and initial results. Acta Cytol 34:627–631, 1990Google Scholar
  3. 3.
    Tobi M, Feng-Chi L, Ronai A: Detection of K-ras mutation in colonic effluent samples from patients without evidence for colorectal carcinoma. J Natl Cancer Inst 86:1007–1010, 1994Google Scholar
  4. 4.
    Tobi M, O'Kieffe D, Trujillo N, Nochomovitz LE, Steinberg WM: Detection of carcinoembryonic antigen in colonic effluent by specific anti-CEA monoclonal antibodies. Cancer Lett 67:47–54, 1992Google Scholar
  5. 5.
    Tobi M, Steinberg W, Henry J, Nochomovitz LE: Cancer associated antigen CA19–9 in colonic effluent of patients with neoplasia of the colon and inflammatory bowel disease. Cancer Lett 60:9–13, 1991Google Scholar
  6. 6.
    Kristinsson J, Roseth A, Fagerhol MKR, Aadland E, Schjonsby H, Bormer OP, Raknerud N, Nygaard K: Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41:316–321, 1998Google Scholar
  7. 7.
    Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of the ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102–105, 1992Google Scholar
  8. 8.
    Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP: Colorectal cancer screening by deletion of altered human DNA in the stool: feasibility of a multitarget assay panel. Gastroenterology 119:1219–1227, 2000Google Scholar
  9. 9.
    Tobi M: Polyps as biomarkers. Front Biosci 4:d329–388, 1999; www.bioscience.orgGoogle Scholar
  10. 10.
    Tobi M, Darmon E, Phillips T, Heller T, Rozen P, Nochomovitz LE, Steinberg WM: Increased expression of a putative adenoma associated antigen in precolonoscopic effluent of patients with colorectal cancer. Cancer Lett 51:21–25, 1990Google Scholar
  11. 11.
    Tobi M, Maliakkal BJ, Zitron I, Alousi M, Goo BG, Nochomovitz LE, Luk GD: Colonic effluent adenoma-associated antigen correlated with colorectal cancer is a membrane-bound glycoprotein. Cancer Lett 67:61–69, 1992Google Scholar
  12. 12.
    Tobi M, Elitsur Y, Moyer MP, Halline A, Deutsch M, Nochomovitz L, Luk GD: Mucosal origin and shedding of an early colonic tumor marker defined by Adnab-9 monoclonal antibody. Scand/J Gastroenterol 28:1025–1034, 1993Google Scholar
  13. 13.
    Tobi M, Darmon E, Rozen P, Epstein N, Konikoff F, Stadler Y, Harpaz N, Fink AK, Bentwich Z, Maliakkal B, Luk GD: Oral colon lavage solutions may interfere with ELISA detection of tumor associated antigens in colonic effluent. Dig Dis Sci 36:1448–1452, 1991Google Scholar
  14. 14.
    Tobi M, Darmon E, Rozen P, Avigdor S, Rattan J, Santo M, Barnea E: Biotransformation in colorectal neoplasia. Scand J Gastroenterol 28:958–962, 1993Google Scholar
  15. 15.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with Folin phenol reagent. J Biol Chem 193:265–275, 1951Google Scholar
  16. 16.
    Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ: Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 112:594–642, 1997Google Scholar
  17. 17.
    Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. Ca Cancer J Clin 50:7–33, 2000Google Scholar
  18. 18.
    Powell J: Katie's crusade. Good Housekeeping October: 124–192, 1998Google Scholar
  19. 19.
    Smith RA, Mettlin CJ, Davis KJ, Eyre H: American Cancer Society guidelines for the early detection of cancer. Ca Cancer J Clin 50:34–49, 2000Google Scholar
  20. 20.
    Rozen P: Screening for colorectal neoplasia in the Tel Aviv area: Cumulative data 1979-89 and initial conclusions. Isr J Med Sci 28(1 suppl):8–20, 1992Google Scholar
  21. 21.
    Yuan M, Xhang X, Leu Y, Tobi M: Sensitivity of fecal Adnab-9 testing for colorectal neoplasia. Gastroenterology, 110:A619, 1996 (abstract)Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Martin Tobi
    • 1
    • 2
  • Shivkumar Prabhu
    • 1
  • Rhonda E. Gage
    • 3
  • Tashia Orr
    • 3
  • Michael J. Lawson
    • 3
  1. 1.Department of MedicineJohn D. Dingell VAMCDetroitUSA
  2. 2.Center for Molecular Medicine and GeneticsWayne State University School of MedicineUSA
  3. 3.Kaiser Permanente Medical GroupSacramentoUSA

Personalised recommendations